Shanghai Henlius Biotech's (HKG:2696) new drug application for HLX14 has been accepted by China's National Medical Products Administration, a Tuesday Hong Kong bourse filing said.
The indications for the drug include the treatment of osteoporosis in postmenopausal women and men at high risk of fractures, as well the treatment of glucocorticoid-induced osteoporosis.